A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Conditions:   Lupus Nephritis;   Lupus Nephritis - World Health Organization (WHO) Class III;   Lupus Nephritis - WHO Class IV Interventions:   Biological: KYV-101 anti-CD19 CAR-T cell therapy;   Drug: Standard lymphodepletion regimen Sponsor:   Kyverna Therapeutics Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials